midazolam and glpg0634

midazolam has been researched along with glpg0634 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Desrivot, J; Harrison, P; Namour, F; Tasset, C; Van der Aa, A; van't Klooster, G	1

Trials

1 trial(s) available for midazolam and glpg0634

Article	Year
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions. Drug metabolism letters, 2016, Volume: 10, Issue:1 Topics: Adult; Animals; Antirheumatic Agents; Biotransformation; CHO Cells; Cricetulus; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Glucuronosyltransferase; Humans; Janus Kinase 1; Male; Membrane Transport Proteins; Methotrexate; Microsomes, Liver; Midazolam; Middle Aged; Protein Kinase Inhibitors; Pyridines; Recombinant Proteins; Risk Assessment; Substrate Specificity; Transfection; Triazoles	2016

Article

Year

Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.

Drug metabolism letters, 2016, Volume: 10, Issue:1

Topics: Adult; Animals; Antirheumatic Agents; Biotransformation; CHO Cells; Cricetulus; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Glucuronosyltransferase; Humans; Janus Kinase 1; Male; Membrane Transport Proteins; Methotrexate; Microsomes, Liver; Midazolam; Middle Aged; Protein Kinase Inhibitors; Pyridines; Recombinant Proteins; Risk Assessment; Substrate Specificity; Transfection; Triazoles

2016